This milestone reflects the strength of our preclinical package and the potential of our MabPair platform to generate differentiated dual-target antibody therapeutics.”
— Wei Yan, Ph.D. CEO of Sound Biologics

BOTHELL, WA, UNITED STATES, November 7, 2025 /EINPresswire.com/ -- Sound Biologics today announced that the U.S. Food and Drug Administration (FDA) has completed its safety review of the company’s Investigational New Drug (IND) application for QLP3119 Injection (PSB219) and issued a “Study May Proceed” letter authorizing initiation of clinical testing in the United States.

The clinical trial will be a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple subcutaneous doses of QLP3119 Injection in healthy subjects. QLP3119 simultaneously targets TSLP and IL-33, two upstream epithelial cytokines that drive overlapping but distinct inflammatory pathways contributing to airway hyper-responsiveness in the lungs. By blocking both targets, QLP3119 can achieve broader and more durable suppression of airway inflammation than single-pathway blockade. Nonclinical studies demonstrated enhanced pharmacologic activity and a well-defined mechanism of action, supporting its advancement as a dual-specific biologic for respiratory inflammation.

“Our goal with QLP3119 is to create an effective treatment for patients with severe asthma and COPD that do not respond to current therapies.” Dr. Yan added. “We look forward to advancing this promising candidate through clinical development.”

About Sound Biologics
Sound Biologics is a clinical-stage biopharmaceutical company based in Bothell, Washington, dedicated to developing innovative antibody-based therapeutics. The company’s pipeline includes programs in oncology, immunology, and neurology. One of its first MabPair products, PSB205/QL1706, was approved in China in 2024 for the treatment of metastatic cervical cancer.

For more information, contact:

WEI YAN
Sound Biologics
+1 425-398-2021
[email protected]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]